|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Boehringer Ingelheim Pharmaceuticals |
|---|---|
| Information provided by: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00936208 |
Purpose
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension
| Condition |
|---|
|
Hypertension |
| Study Type: | Observational |
| Study Design: | Cohort, Prospective |
| Official Title: | To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor |
| Estimated Enrollment: | 3600 |
| Study Start Date: | May 2009 |
| Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Hypertensive patients in the Kingdom of Saudi Arabia, Egypt and United Arab Emirates
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Boehringer Ingelheim Study Coordinator | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
Show 102 Study Locations| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
| Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
| Study ID Numbers: | 502.584 |
| Study First Received: | July 8, 2009 |
| Last Updated: | January 13, 2010 |
| ClinicalTrials.gov Identifier: | NCT00936208 History of Changes |
| Health Authority: | Egypt: Ministry of Health and Population; Saudi Arabia: Ministry of Health; United Arab Emirates: General Auth for Health Services Abu Dhabi |
|
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors |
Cardiovascular Diseases Telmisartan Pharmacologic Actions Protease Inhibitors Hypertension |